Table 1. Clinical and pathologic characteristics of patients with EGFR mutant NSCLC before and after EGFR-TKI therapy.
Characteristics | N = 69 |
---|---|
Age (mean, Years) | 60.2 (34–78.4) |
Sex | |
Men | 19 (27.5%) |
Women | 50 (72.5%) |
ECOG Performance status | |
0 | 47 (68.1%) |
1 | 18 (26.1%) |
2 | 4 (5.8%) |
Smoking history | |
Current or ex-smoker | 15 (21.7%) |
Never smoker | 54 (78.3%) |
Clinical stage at diagnosis | |
Stage IIIB | 5 (7.2%) |
Stage IVa | 19 (27.5%) |
Stage IVb | 45 (65.2%) |
Presence of brain metastasis | 24 (34.7%) |
Histology | |
Adenocarcinoma | 66 (95.7%) |
Adenosquamous cell carcinoma | 2 (2.9%) |
Squamous cell carcinoma | 1 (1.4%) |
EGFR mutation at diagnosis | |
Exon 19 del | 49 (71.1%) |
Exon 21 L858R/L861Q | 18 (26.1%) |
Exon 18 G719X | 1 (1.4%) |
Exon 20 S768I | 1 (1.4%) |
Rebiopsy histology | |
Adenocarcinoma | 59 (85.6%) |
Small cell carcinoma/neuroendocrine carcinoma | 4 (5.8%) |
Adenosquamous/Squamous cell carcinoma | 4 (5.8%) |
Large cell carcinoma | 1 (1.4% |
Sarcomatoid carcinoma | 1 (1.4%) |
Acquired EGFR Exon 20 T790M mutation in rebiopsy | |
Exon20 T790M | 22 (31.9%) |
No exon20 T790M | 40 (58.0%) |
Unknown | 7 (10.1%) |
Treatment just before rebiopsy | |
EGFR-TKIs | 57 (82.6%) |
Cytotoxic chemotherapy | 12 (17.4%) |
Median PFS for EGFR-TKIs | Median Months (95% CI) |
First line (n = 53) | 13.4 (11.7–15.0) |
Second line (n = 16) | 20.4 (8.7–32.5) |